戻る
AstraZeneca Reports Strong Q2 2025 Performance Amid Oncology Growth and Regulatory Advancements
戻る
株式ニュース
テーマ
AstraZeneca Reports Strong Q2 2025 Performance Amid Oncology Growth and Regulatory Advancements
AstraZeneca Reports Strong Q2 2025 Performance Amid Oncology Growth and Regulatory Advancements
Edgen Stock
·
Sep 25 2025, 12:59
共有先
共有先
リンクをコピー
ソース：
[1] AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
[2] AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors (NASDAQ:AZN)
[3] AstraZeneca's Tezspire: A Game-Changer in Chronic Sinusitis? Regulatory Hurdles and Market Access Potential in the EU - AInvest
Edgen Stock·Sep 25 2025, 12:59Edgen Stock·Sep 25 2025, 12:59
Edgen Stock·Sep 25 2025, 12:59